JP Morgan Chase
MSLE

JP Morgan Chase’s Satellos Bioscience MSLE Stock Holding History

JP Morgan Chase’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48K Buy
+315
New +$2.16K ﹤0.01% 7185

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

JP Morgan Chase's MSLE Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Satellos Bioscience (MSLE) in Q2 2026: 315 shares worth $2.48K. The stake represents ﹤0.01% of the portfolio and ranks #7185 among its holdings.

26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • JP Morgan Chase held 315 shares of Satellos Bioscience worth $2.48K as of Q2 2026.
  • Satellos Bioscience was a new JP Morgan Chase position in Q2 2026.
  • Satellos Bioscience made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7185 holding.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.